TCRX
TScan Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-39/100
Last price
0.28
▲ 0.00 (0.54%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.28
Prev close
0.28
Day high
0.28
Day low
0.26
Volume
540.46K
Market cap
$18.77M
P/E (TTM)
—
52W range
0.26 – 2.57
Day trading desk
Gap from prior close
+1.78%
Prior close 0.28
VWAP
0.27
+1.42% from price
Relative volume
0.68×
Normal
Session range
9.29%
0.26 – 0.29
Position in range
58%
Mid range
ATR (14D)
0.03
10.94% of price
Prior day high
0.30
PDH
Prior day low
0.26
PDL
Bid / ask spread
—
Quote not published
Session volume
553.81K
Avg 812.54K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-12.10%
-14.0%
1M
-19.74%
-21.2%
3M
-73.88%
-77.3%
6M
-73.88%
-88.8%
YTD
-72.31%
-86.3%
1Y
-86.49%
-102.2%
3Y
-89.86%
-171.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TCRX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
128.10K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Dec 23, 25 | LYNX1 CAPITAL MANAGEMENT LP Beneficial Owner of more than 10% of a Class of Security |
BUY | 161.80K | $145.53K | Indirect |
| May 20, 25 | LYNX1 CAPITAL MANAGEMENT LP Beneficial Owner of more than 10% of a Class of Security |
BUY | 2.59M | $3.11M | Indirect |
| Dec 13, 24 | LYNX1 CAPITAL MANAGEMENT LP Beneficial Owner of more than 10% of a Class of Security |
BUY | 131.80K | $385.77K | Indirect |
| Nov 15, 24 | LYNX1 CAPITAL MANAGEMENT LP Beneficial Owner of more than 10% of a Class of Security |
BUY | 947 | $4.11K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
LYNX1 CAPITAL MANAGEMENT LP |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
Fundamentals
Market cap$18.77M
Enterprise value$9.40M
Revenue (TTM)$7.11M
Gross profit$-88.32M
EBITDA$-115.66M
Net income$-117.71M
EPS (TTM)$-0.91
Free cash flow$-79.92M
Total cash$100.16M
Total debt$90.89M
Book value / share$1.02
Shares outstanding63.50M
Float54.36M
Short % of float4.83%
Dividend yield0.00%
Beta (5Y)1.14
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.48
PEG ratio—
Price / sales—
Price / book0.27
EV / revenue1.32
EV / EBITDA-0.08
Gross margin0.00%
Operating margin-2901.33%
Profit margin0.00%
Return on equity-95.80%
Return on assets-31.53%
Debt / equity131.69
Current ratio3.37
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $10.32M | $2.82M | $21.05M | $13.54M | +266.7% |
| Operating revenue | $10.32M | $2.82M | $21.05M | $13.54M | +266.7% |
| Research & development | $114.15M | $107.35M | $88.15M | $59.82M | +6.3% |
| Selling, general & admin | $31.33M | $29.56M | $25.49M | $20.35M | +6.0% |
| Total operating expense | $146.14M | $137.64M | $114.51M | $80.17M | +6.2% |
| Operating income | -$135.81M | -$134.82M | -$93.46M | -$66.64M | -0.7% |
| Net interest income | $6.05M | $8.41M | $4.24M | $415.00K | -28.1% |
| Pre-tax income | -$129.77M | -$127.50M | -$89.22M | -$66.22M | -1.8% |
| Net income | -$129.77M | -$127.50M | -$89.22M | -$66.22M | -1.8% |
| Net income to common | -$129.77M | -$127.50M | -$89.22M | -$66.22M | -1.8% |
| Basic EPS | -1.00 | -1.14 | -1.36 | -2.75 | +12.3% |
| Diluted EPS | -1.00 | -1.14 | -1.36 | -2.75 | +12.3% |
| EBIT | -$127.00M | -$123.85M | -$85.46M | -$65.05M | -2.5% |
| EBITDA | -$124.13M | -$119.74M | -$80.10M | -$59.91M | -3.7% |
| Basic shares | 129.78M | 111.99M | 65.60M | 24.05M | +15.9% |
| Diluted shares | 129.78M | 111.99M | 65.60M | 24.05M | +15.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $152.41M | $178.69M | $133.36M | $120.03M | -14.7% |
| Cash & short-term investments | $152.41M | $290.11M | $192.04M | $120.03M | -47.5% |
| Total current assets | $157.21M | $292.72M | $194.24M | $124.13M | -46.3% |
| Property, plant & equipment | $66.45M | $71.60M | $71.23M | $69.20M | -7.2% |
| Total assets | $228.79M | $371.12M | $272.15M | $199.09M | -38.4% |
| Total current liabilities | $18.70M | $35.96M | $29.82M | $17.30M | -48.0% |
| Current debt | — | — | $3.35M | — | — |
| Long-term debt | $32.53M | $32.07M | $26.70M | $29.29M | +1.4% |
| Total debt | $94.14M | $97.38M | $92.43M | $85.98M | -3.3% |
| Total liabilities | $105.67M | $130.15M | $121.28M | $99.66M | -18.8% |
| Retained earnings | -$504.86M | -$375.10M | -$247.60M | -$158.38M | -34.6% |
| Shareholder equity | $123.12M | $240.97M | $150.87M | $99.43M | -48.9% |
| Working capital | $138.51M | $256.77M | $164.42M | $106.82M | -46.1% |
| Net tangible assets | $123.12M | $240.97M | $150.87M | $99.43M | -48.9% |
| Shares issued | 56.90M | 56.59M | 47.83M | 24.23M | +0.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$129.77M | -$127.50M | -$89.22M | -$66.22M | -1.8% |
| Depreciation & amortisation | $2.87M | $4.11M | $5.36M | $5.14M | -30.2% |
| Stock-based compensation | $11.71M | $9.55M | $5.21M | $4.55M | +22.6% |
| Change in working capital | -$18.18M | $5.05M | $17.61M | -$10.23M | -459.7% |
| Operating cash flow | -$135.32M | -$110.82M | -$61.36M | -$66.50M | -22.1% |
| Capital expenditure | -$4.41M | -$3.83M | -$3.15M | -$4.22M | -15.2% |
| Investing cash flow | $109.37M | -$52.61M | -$60.76M | -$4.22M | +307.9% |
| Dividends paid | $0 | $0 | — | — | — |
| Financing cash flow | -$336.00K | $208.76M | $135.44M | $29.36M | -100.2% |
| Free cash flow | -$139.73M | -$114.65M | -$64.50M | -$70.73M | -21.9% |
| End cash position | $157.44M | $183.72M | $138.39M | $125.06M | -14.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.05M | $982.00K | $2.57M | $2.51M | $3.08M | +7.0% |
| Operating revenue | $1.05M | $982.00K | $2.57M | $2.51M | $3.08M | +7.0% |
| Research & development | $23.40M | $21.90M | $20.04M | $31.69M | $32.63M | +6.8% |
| Selling, general & admin | $8.06M | $8.13M | $5.73M | $7.70M | $8.92M | -0.9% |
| Total operating expense | $31.54M | $30.12M | $26.43M | $39.56M | $41.73M | +4.7% |
| Operating income | -$30.49M | -$29.14M | -$23.86M | -$37.05M | -$38.65M | -4.6% |
| Net interest income | $134.00K | $473.00K | $881.00K | $1.34M | $1.70M | -71.7% |
| Pre-tax income | -$30.36M | -$28.67M | -$22.98M | -$35.71M | -$36.95M | -5.9% |
| Net income | -$30.36M | -$28.67M | -$22.98M | -$35.71M | -$36.95M | -5.9% |
| Net income to common | -$30.36M | -$28.67M | -$22.98M | -$35.71M | -$36.95M | -5.9% |
| Basic EPS | -0.23 | -0.22 | -0.18 | -0.28 | -0.28 | -4.5% |
| Diluted EPS | -0.23 | -0.22 | -0.18 | -0.28 | -0.28 | -4.5% |
| EBIT | -$29.66M | -$27.98M | -$22.27M | -$35.01M | -$36.26M | -6.0% |
| EBITDA | -$28.96M | -$27.28M | -$21.55M | -$34.24M | -$35.56M | -6.1% |
| Basic shares | 129.95M | 129.91M | 129.86M | 129.84M | 129.73M | +0.0% |
| Diluted shares | 129.95M | 129.91M | 129.86M | 129.84M | 129.73M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $100.16M | $128.06M | $152.41M | $169.51M | $169.39M | -21.8% |
| Cash & short-term investments | $100.16M | $128.06M | $152.41M | $184.45M | $218.04M | -21.8% |
| Total current assets | $104.40M | $132.77M | $157.21M | $188.16M | $221.13M | -21.4% |
| Property, plant & equipment | $61.97M | $64.13M | $66.45M | $68.74M | $70.62M | -3.4% |
| Total assets | $171.45M | $201.99M | $228.79M | $262.23M | $298.56M | -15.1% |
| Total current liabilities | $30.96M | $19.97M | $18.70M | $29.21M | $31.32M | +55.1% |
| Current debt | $11.71M | — | — | — | — | — |
| Long-term debt | $21.07M | $32.65M | $32.53M | $32.41M | $32.30M | -35.5% |
| Total debt | $90.89M | $92.54M | $94.14M | $95.62M | $96.70M | -1.8% |
| Total liabilities | $102.43M | $105.07M | $105.67M | $118.20M | $121.85M | -2.5% |
| Retained earnings | -$563.89M | -$533.53M | -$504.86M | -$481.88M | -$446.18M | -5.7% |
| Shareholder equity | $69.02M | $96.92M | $123.12M | $144.02M | $176.71M | -28.8% |
| Working capital | $73.44M | $112.80M | $138.51M | $158.96M | $189.81M | -34.9% |
| Net tangible assets | $69.02M | $96.92M | $123.12M | $144.02M | $176.71M | -28.8% |
| Shares issued | 67.78M | 60.10M | 56.90M | 56.75M | 56.75M | +12.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$30.36M | -$28.67M | -$22.98M | -$35.71M | -$36.95M | -5.9% |
| Depreciation & amortisation | $699.00K | $693.00K | $723.00K | $767.00K | $698.00K | +0.9% |
| Stock-based compensation | $2.36M | $2.46M | $2.01M | $3.01M | $3.27M | -4.4% |
| Change in working capital | -$456.00K | $1.11M | -$11.82M | -$359.00K | $386.00K | -141.1% |
| Operating cash flow | -$27.54M | -$24.28M | -$32.00M | -$32.46M | -$33.27M | -13.4% |
| Capital expenditure | -$493.00K | -$70.00K | -$171.00K | -$1.43M | -$1.28M | -604.3% |
| Investing cash flow | -$465.00K | -$70.00K | $14.83M | $32.58M | $48.44M | -564.3% |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $99.00K | $0 | $73.00K | $0 | $116.00K | — |
| Free cash flow | -$28.03M | -$24.35M | -$32.17M | -$33.89M | -$34.55M | -15.1% |
| End cash position | $105.19M | $133.09M | $157.44M | $174.54M | $174.43M | -21.0% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.21 | -0.23 | -12.2% |
| Mar 2026 | -0.17 | -0.22 | -33.3% |
| Dec 2025 | -0.28 | -0.18 | +34.8% |
| Sep 2025 | -0.33 | -0.28 | +15.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.18 | 4 | $471.50K | -81.2% |
| Next quarter | -0.15 | 4 | $425.00K | -83.4% |
| Current year | -0.78 | 4 | $2.92M | -71.7% |
| Next year | -0.57 | 4 | $1.25M | -57.2% |
Analyst targets & ownership
Mean target$1.00
High target$1.00
Low target$1.00
Implied upside261.14%
Analyst count2
ConsensusHOLD
Strong buy / Buy0 / 1
Hold4
Sell / Strong sell0 / 0
Held by insiders0.19%
Held by institutions67.88%
Institutions holding77
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.31
-12.04% from price
SMA 20
0.32
-14.00% from price
SMA 50
0.55
-49.38% from price
SMA 100
0.76
-63.43% from price
SMA 200
0.92
-70.03% from price
EMA 12
0.32
-12.61% from price
EMA 26
0.39
-28.68% from price
EMA 50
0.51
-46.18% from price
RSI (14)
24.7
Oversold
MACD (12,26,9)
-0.07
Hist 0.01
ATR (14)
0.03
10.94% of price
Realised vol 30D
170.9%
Annualised
Bollinger upper
0.37
20, 2σ
Bollinger lower
0.28
20, 2σ
50 / 200 cross
Death
0.55 vs 0.92
Trend bias
Below 200
-70.03%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.37
More volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
170.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-89.1%
Peak to trough
Max drawdown 5Y
-97.1%
Peak to trough
ATR 14
0.03
10.94% of price
Beta (reported)
1.14
5Y monthly, from filing
Short interest
Shares short
2.28M
Prior 1.60M
Change vs prior
+42.4%
Shorts adding
% of float
4.83%
Normal
% of shares out
3.36%
Against total outstanding
Days to cover
2.1
Liquid
Float
54.36M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 8, 26 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Sep 3, 26 | Wedbush | DOWNGRADE | Outperform | Neutral |
| Sep 2, 26 | Needham | DOWNGRADE | Buy | Hold |
| Aug 12, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 23, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jun 23, 26 | Needham | MAINTAINED | Buy | Buy |
| Mar 5, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Nov 13, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 4, 25 | BTIG | DOWNGRADE | Buy | Neutral |
| Nov 4, 25 | Needham | MAINTAINED | Buy | Buy |
| May 7, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 8, 25 | Needham | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-30
Corporate Changes & Voting Matters
8-K · 2026-09-11
Corporate Changes & Voting Matters
8-K · 2026-09-02
Corporate Changes & Voting Matters
8-K · 2026-08-18
Periodic Financial Reports
10-Q · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-06-22
Corporate Changes & Voting Matters
8-K · 2026-05-22
Periodic Financial Reports
10-Q · 2026-05-06
Headlines
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
BioPharma Dive · 34d ago
TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program
InvestorsHub · 35d ago
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
GlobeNewswire · 35d ago
Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership?
Simply Wall St. · 42d ago
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 56d ago
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · 56d ago
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 62d ago
Cell and gene therapy manufacturers turn to specialist automation partners
Pharmaceutical Technology · 68d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.